BRPI0620229B8 - formulações farmaceuticas e processos de produção da ditas formulações - Google Patents
formulações farmaceuticas e processos de produção da ditas formulaçõesInfo
- Publication number
- BRPI0620229B8 BRPI0620229B8 BRPI0620229A BRPI0620229A BRPI0620229B8 BR PI0620229 B8 BRPI0620229 B8 BR PI0620229B8 BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 B8 BRPI0620229 B8 BR PI0620229B8
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- production processes
- pharmaceutical
- pharmaceutical formulations
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0526419.7A GB0526419D0 (en) | 2005-12-23 | 2005-12-23 | Formulation |
GB0526419.7 | 2005-12-23 | ||
PCT/GB2006/004927 WO2007072061A2 (en) | 2005-12-23 | 2006-12-22 | Crystalline pyrimidine nucleoside derivatives suspensions in capsules |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0620229A2 BRPI0620229A2 (pt) | 2011-11-01 |
BRPI0620229A8 BRPI0620229A8 (pt) | 2018-01-02 |
BRPI0620229B1 BRPI0620229B1 (pt) | 2020-09-15 |
BRPI0620229B8 true BRPI0620229B8 (pt) | 2021-05-25 |
Family
ID=35841215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0620229A BRPI0620229B8 (pt) | 2005-12-23 | 2006-12-22 | formulações farmaceuticas e processos de produção da ditas formulações |
Country Status (17)
Country | Link |
---|---|
US (1) | US8497291B2 (pt) |
EP (1) | EP1962814B1 (pt) |
JP (2) | JP5443763B2 (pt) |
CN (1) | CN101346132B (pt) |
AU (1) | AU2006327951B2 (pt) |
BR (1) | BRPI0620229B8 (pt) |
CA (1) | CA2633308C (pt) |
DK (1) | DK1962814T3 (pt) |
ES (1) | ES2672106T3 (pt) |
GB (1) | GB0526419D0 (pt) |
HK (1) | HK1126412A1 (pt) |
HU (1) | HUE039368T2 (pt) |
IL (1) | IL192348A (pt) |
PT (1) | PT1962814T (pt) |
RU (1) | RU2428972C2 (pt) |
TR (1) | TR201808182T4 (pt) |
WO (1) | WO2007072061A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
WO2008132443A1 (en) * | 2007-04-25 | 2008-11-06 | Cyclacel Limited | Use of sapacitabine to treat proliferative disease |
US8124593B2 (en) | 2007-11-05 | 2012-02-28 | Cyclacel Limited | Methods of treatment using sapacitabine |
GB0808357D0 (en) | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
EP2307002B1 (en) | 2008-06-09 | 2013-01-02 | Cyclacel Limited | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
CN102414216B (zh) * | 2009-05-15 | 2015-01-21 | 德鲁塔负富莱制药股份有限公司 | 1-(2’-氰基-2’-脱氧-β-D-阿拉伯呋喃糖基)胞嘧啶一盐酸盐的稳定型结晶 |
MX2012013872A (es) | 2010-06-02 | 2013-04-03 | Astellas Deutschland Gmbh | Formas de dosificacion oral de bendamustina. |
PL2696878T3 (pl) | 2011-04-14 | 2020-01-31 | Cyclacel Limited | Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej |
JP5873375B2 (ja) * | 2012-04-03 | 2016-03-01 | 中日本カプセル 株式会社 | ソフトカプセル及びソフトカプセルの製造方法 |
JP6286421B2 (ja) | 2012-05-15 | 2018-02-28 | サイクラセル リミテッド | サパシタビン及びセリシクリブの投与レジメン |
MX2015011074A (es) * | 2013-02-28 | 2016-03-09 | Pronova Biopharma Norge As | Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma. |
CN106963742B (zh) * | 2016-11-07 | 2021-02-23 | 澳门大学 | 中药固液胶囊及其制备方法 |
WO2019081951A1 (en) | 2017-10-27 | 2019-05-02 | Cyclacel Limited | DOSAGE REGIME |
WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69130683T2 (de) * | 1991-04-22 | 1999-05-06 | Otsuka Pharma Co Ltd | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
CA2079413C (en) | 1991-09-30 | 2003-09-09 | Masakatsu Kaneko | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use |
DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
US5599922A (en) * | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
KR19980073479A (ko) * | 1997-03-14 | 1998-11-05 | 한스루돌프하우스, 니콜케르커 | 사이클로스포린-함유 연질캅셀제 |
NL1003503C2 (nl) * | 1996-07-04 | 1998-01-07 | Negma Steba International Dev | Farmaceutische samenstelling voor orale toediening. |
GB9918885D0 (en) * | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
US6908906B2 (en) * | 2001-02-09 | 2005-06-21 | Sankyo Company, Limited | Crystalline forms of pyrimidine nucleoside derivative |
JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
JP2005531495A (ja) * | 2001-12-21 | 2005-10-20 | シャイア ラボラトリーズ,インコーポレイテッド | 高い物理的安定性を有する経口カプセル製剤 |
JP5096658B2 (ja) * | 2003-10-06 | 2012-12-12 | 株式会社三協 | 生物学的利用能を向上させたソフトカプセル |
US20050249802A1 (en) * | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
GB0413730D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
-
2005
- 2005-12-23 GB GBGB0526419.7A patent/GB0526419D0/en not_active Ceased
-
2006
- 2006-12-22 DK DK06831479.8T patent/DK1962814T3/en active
- 2006-12-22 ES ES06831479.8T patent/ES2672106T3/es active Active
- 2006-12-22 TR TR2018/08182T patent/TR201808182T4/tr unknown
- 2006-12-22 BR BRPI0620229A patent/BRPI0620229B8/pt not_active IP Right Cessation
- 2006-12-22 JP JP2008546637A patent/JP5443763B2/ja not_active Expired - Fee Related
- 2006-12-22 CA CA2633308A patent/CA2633308C/en active Active
- 2006-12-22 US US12/097,912 patent/US8497291B2/en active Active
- 2006-12-22 AU AU2006327951A patent/AU2006327951B2/en not_active Ceased
- 2006-12-22 PT PT68314798T patent/PT1962814T/pt unknown
- 2006-12-22 HU HUE06831479A patent/HUE039368T2/hu unknown
- 2006-12-22 CN CN2006800488748A patent/CN101346132B/zh not_active Expired - Fee Related
- 2006-12-22 RU RU2008130411/15A patent/RU2428972C2/ru active
- 2006-12-22 WO PCT/GB2006/004927 patent/WO2007072061A2/en active Application Filing
- 2006-12-22 EP EP06831479.8A patent/EP1962814B1/en active Active
-
2008
- 2008-06-19 IL IL192348A patent/IL192348A/en active IP Right Grant
-
2009
- 2009-06-11 HK HK09105247.1A patent/HK1126412A1/xx not_active IP Right Cessation
-
2013
- 2013-06-04 JP JP2013117637A patent/JP2013189463A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20090074856A1 (en) | 2009-03-19 |
HK1126412A1 (en) | 2009-09-04 |
RU2008130411A (ru) | 2010-01-27 |
CA2633308C (en) | 2014-06-17 |
DK1962814T3 (en) | 2018-08-06 |
AU2006327951A1 (en) | 2007-06-28 |
BRPI0620229A8 (pt) | 2018-01-02 |
PT1962814T (pt) | 2018-06-22 |
RU2428972C2 (ru) | 2011-09-20 |
WO2007072061A2 (en) | 2007-06-28 |
JP5443763B2 (ja) | 2014-03-19 |
TR201808182T4 (tr) | 2018-07-23 |
EP1962814B1 (en) | 2018-04-25 |
BRPI0620229B1 (pt) | 2020-09-15 |
AU2006327951B2 (en) | 2012-09-06 |
US8497291B2 (en) | 2013-07-30 |
IL192348A (en) | 2016-02-29 |
CA2633308A1 (en) | 2007-06-28 |
BRPI0620229A2 (pt) | 2011-11-01 |
CN101346132A (zh) | 2009-01-14 |
GB0526419D0 (en) | 2006-02-08 |
IL192348A0 (en) | 2009-08-03 |
EP1962814A2 (en) | 2008-09-03 |
HUE039368T2 (hu) | 2018-12-28 |
CN101346132B (zh) | 2013-01-16 |
JP2013189463A (ja) | 2013-09-26 |
JP2009520797A (ja) | 2009-05-28 |
ES2672106T3 (es) | 2018-06-12 |
WO2007072061A3 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0620229B8 (pt) | formulações farmaceuticas e processos de produção da ditas formulações | |
BR0207726A (pt) | Sais farmacêuticos | |
BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
ECSP088414A (es) | Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria | |
BRPI0412689A (pt) | derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele | |
UY30762A1 (es) | Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol | |
GT199900203A (es) | Composiciones de celecoxib. | |
NI200600240A (es) | FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
BRPI0517846A (pt) | azaindolcarboxamidas | |
BRPI0518904A2 (pt) | formulaÇÕes de nepafenac tàpicas | |
BRPI0511874A (pt) | derivados da pirrolopiridina | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
BRPI0908052A2 (pt) | Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada | |
ECSP099776A (es) | Moduladores de la gamma secretasa | |
CR10229A (es) | Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
BRPI0414864A (pt) | composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida | |
BR112012026596A2 (pt) | método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas | |
UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
NO20084478L (no) | Konjugerte lipidderivater | |
ATE452120T1 (de) | Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür | |
BRPI0518789A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete | |
EA201070484A1 (ru) | Новые конъюгаты нейртурина для фармацевтического применения | |
BRPI0408848B8 (pt) | composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação | |
BRPI0416188A (pt) | formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ESCLARECA O DEPOSITANTE A DIVERGENCIA EXISTENTE NO NOME DO INVENTOR ROBERT WESTWOOD CONSTANTE DA PUBLICACAO WO NO 2007/072061 DE 28/06/2007 E O EXISTENTE NA PETICAO INICIAL. |
|
B25G | Requested change of headquarter approved |
Owner name: CYCLACEL LIMITED (GB) |
|
B25G | Requested change of headquarter approved |
Owner name: CYCLACEL LIMITED (GB) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2754 DE 17-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |